Discovery of coding genetic variants influencing diabetes-related serum biomarkers and their impact on risk of type 2 diabetes.

CONTEXT Type 2 diabetes (T2D) prevalence is spiraling globally, and knowledge of its pathophysiological signatures is crucial for a better understanding and treatment of the disease. OBJECTIVE We aimed to discover underlying coding genetic variants influencing fasting serum levels of nine biomarkers associated with T2D: adiponectin, C-reactive protein, ferritin, heat shock 70-kDa protein 1B, IGF binding protein 1 and IGF binding protein 2, IL-18, IL-2 receptor-α, and leptin. DESIGN AND PARTICIPANTS A population-based sample of 6215 adult Danes was genotyped for 16 340 coding single-nucleotide polymorphisms and were tested for association with each biomarker. Identified loci were tested for association with T2D through a large-scale meta-analysis involving up to 17 024 T2D cases and up to 64 186 controls. RESULTS We discovered 11 associations between single-nucleotide polymorphisms and five distinct biomarkers at a study-wide P < 3.4 × 10(-7). Nine associations were novel: IL18: BIRC6, RAD17, MARVELD2; ferritin: F5; IGF binding protein 1: SERPING1, KLKB, GCKR, CELSR2, and heat shock 70-kDa protein 1B: CFH. Three of the identified loci (CELSR2, HNF1A, and GCKR) were significantly associated with T2D, of which the association with the CELSR2 locus has not been shown previously. CONCLUSION The identified loci influence processes related to insulin signaling, cell communication, immune function, apoptosis, DNA repair, and oxidative stress, all of which could provide a rationale for novel diabetes therapeutic strategies.

[1]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[2]  P. Poulsen,et al.  Heritability of Type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance – a population-based twin study , 1999, Diabetologia.

[3]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[4]  M. Stoffel,et al.  Hepatocyte nuclear factor-1α is an essential regulator of bile acid and plasma cholesterol metabolism , 2001, Nature Genetics.

[5]  M. Stoffel,et al.  Loss of HNF-1alpha function in mice leads to abnormal expression of genes involved in pancreatic islet development and metabolism. , 2001, Diabetes.

[6]  Charlotte Glümer,et al.  A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99 (1) , 2003, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[7]  M. Zonderland,et al.  IGF-Binding Protein-1 Levels Are Related to Insulin-Mediated Glucose Disposal and Are a Potential Serum Marker of Insulin Resistance , 2007, Diabetes Care.

[8]  Marcia M. Nizzari,et al.  Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels , 2007, Science.

[9]  Dolores Corella,et al.  Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans , 2008, Nature Genetics.

[10]  M. Rieder,et al.  Common Missense Variant in the Glucokinase Regulatory Protein Gene Is Associated With Increased Plasma Triglyceride and C-Reactive Protein but Lower Fasting Glucose Concentrations , 2008, Diabetes.

[11]  N. Cook,et al.  Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. , 2008, American journal of human genetics.

[12]  Børge G Nordestgaard,et al.  Genetically elevated C-reactive protein and ischemic vascular disease. , 2008, The New England journal of medicine.

[13]  Torben Hansen,et al.  Development of a Type 2 Diabetes Risk Model From a Panel of Serum Biomarkers From the Inter99 Cohort , 2009, Diabetes Care.

[14]  Christian Gieger,et al.  Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts , 2009, Nature Genetics.

[15]  Christian Gieger,et al.  Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium , 2009, Nature Genetics.

[16]  J. Wylie-Rosett,et al.  The role of insulin‐like growth factor‐I and its binding proteins in glucose homeostasis and type 2 diabetes , 2009, Diabetes/metabolism research and reviews.

[17]  T. Hansen,et al.  Validation of a Multimarker Model for Assessing Risk of Type 2 Diabetes from a Five-Year Prospective Study of 6784 Danish People (Inter99) , 2009, Journal of diabetes science and technology.

[18]  Shahrul Mt-Isa,et al.  Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. , 2009, JAMA.

[19]  Ayellet V. Segrè,et al.  Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis , 2010, Nature Genetics.

[20]  J. Shaw,et al.  Global estimates of the prevalence of diabetes for 2010 and 2030. , 2010, Diabetes research and clinical practice.

[21]  L. Groop,et al.  Genetics of type 2 diabetes. , 2011, Clinical chemistry.

[22]  P. Elliott,et al.  Meta-Analysis of Genome-Wide Association Studies in >80 000 Subjects Identifies Multiple Loci for C-Reactive Protein Levels , 2011, Circulation.

[23]  N. Yuldasheva,et al.  Increasing Circulating IGFBP1 Levels Improves Insulin Sensitivity, Promotes Nitric Oxide Production, Lowers Blood Pressure, and Protects Against Atherosclerosis , 2012, Diabetes.

[24]  M. McCarthy,et al.  Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes , 2012, Diabetologia.

[25]  T. Hansen,et al.  Validation of a multi-marker model for the prediction of incident type 2 diabetes mellitus: Combined results of the Inter99 and Botnia studies , 2012, Diabetes & vascular disease research.

[26]  Tanya M. Teslovich,et al.  Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes , 2012, Nature Genetics.

[27]  Yiran Guo,et al.  Gene-centric meta-analyses of 108 912 individuals confirm known body mass index loci and reveal three novel signals. , 2013, Human molecular genetics.

[28]  R. Wahl,et al.  Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors , 2013, Nature.

[29]  B. Nordestgaard,et al.  Pleiotropic effects of HNF1A rs1183910 in a population-based study of 60,283 individuals , 2014, Diabetologia.

[30]  Kari Stefansson,et al.  Identification of low-frequency and rare sequence variants associated with elevated or reduced risk of type 2 diabetes , 2014, Nature Genetics.

[31]  S. Bandinelli,et al.  Novel gene variants predict serum levels of the cytokines IL-18 and IL-1ra in older adults. , 2014, Cytokine.

[32]  L. Groop,et al.  Type 2 diabetes susceptibility gene variants predispose to adult-onset autoimmune diabetes , 2014, Diabetologia.

[33]  Thomas Meitinger,et al.  Loss-of-function mutations in SLC30A8 protect against type 2 diabetes , 2014, Nature Genetics.

[34]  Matti Pirinen,et al.  Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins , 2014, Nature Communications.

[35]  T. Hansen,et al.  Cohort Profile: the Health2006 cohort, research centre for prevention and health. , 2014, International journal of epidemiology.

[36]  T. Hansen,et al.  Genetic susceptibility to type 2 diabetes and obesity: from genome-wide association studies to rare variants and beyond , 2014, Diabetologia.

[37]  Pierre Fontanillas,et al.  Association of exome sequences with plasma C-reactive protein levels in >9000 participants. , 2015, Human molecular genetics.